» Articles » PMID: 34562537

Revealing the Role of MiRNA-489 As a New Onco-suppressor Factor in Different Cancers Based on Pre-clinical and Clinical Evidence

Abstract

Recently, microRNAs (miRNAs) have shown to be potential therapeutic, diagnostic and prognostic targets in disease therapy. These endogenous non-coding RNAs contribute to regulation of different cellular events that are necessary for maintaining physiological condition. Dysregulation of miRNAs is correlated with development of various pathological events such as neurological disorders, cardiovascular diseases, and cancer. miRNA-489 is a new emerging miRNA and studies are extensively investigating its role in pathological conditions. Herein, potential function of miRNA-489 as tumor-suppressor in various cancers is described. miRNA-489 is able to sensitize cancer cells into chemotherapy by disrupting molecular pathways involved in cancer growth such as PI3K/Akt, and induction of apoptosis. The PROX1 and SUZ12 as oncogenic pathways, are affected by miRNA-489 in suppressing metastasis of cancer cells. Wnt/β-catenin as an oncogenic factor ensuring growth and malignancy of tumors is inhibited via miRNA-489 function. For enhancing drug sensitivity of tumors, restoring miRNA-489 expression is a promising strategy. The lncRNAs can modulate miRNA-489 expression in tumors and studies about circRNA role in miRNA-489 modulation should be performed. The expression level of miRNA-489 is a diagnostic tool for tumor detection. Besides, down-regulation of miRNA-489 in tumors provides unfavorable prognosis.

Citing Articles

Molecular mechanisms of miR-192 in cancer: a biomarker and therapeutic target.

Yang Y, Razak S, Ismail I, Ma Y, Yunus M Cancer Cell Int. 2025; 25(1):94.

PMID: 40087755 DOI: 10.1186/s12935-025-03666-5.


Nanoliposomes as nonviral vectors in cancer gene therapy.

Yildiz S, Entezari M, Paskeh M, Mirzaei S, Kalbasi A, Zabolian A MedComm (2020). 2024; 5(7):e583.

PMID: 38919334 PMC: 11199024. DOI: 10.1002/mco2.583.


Curcumin in treatment of hematological cancers: Promises and challenges.

Entezari M, Tayari A, Paskeh M, Kheirabad S, Naeemi S, Taheriazam A J Tradit Complement Med. 2024; 14(2):121-134.

PMID: 38481552 PMC: 10927384. DOI: 10.1016/j.jtcme.2023.10.004.


MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer.

Wu R, Zhang B, He M, Kang Y, Zhang G J Cancer Res Clin Oncol. 2023; 149(18):16753-16761.

PMID: 37728700 DOI: 10.1007/s00432-023-05404-8.


hsa_circ_0000519 promotes the progression of lung adenocarcinoma through the hsa-miR-1296-5p/DARS axis.

Tu G, Peng W, Peng X, Zhao Z, Shi S, Cai Q Am J Cancer Res. 2023; 13(8):3342-3367.

PMID: 37693148 PMC: 10492121.